U.S Class(es): 006, 018, 044, 046, 051, 052
Class Status: Active
First Use: Feb-06-2019
First Use in Commerce: Feb-06-2019
| Name | Teva Pharmaceuticals USA, Inc. |
|---|---|
| Address | 400 Interpace Drive Building A Parsippany, NJ 07054 United States |
| Date | Description | Action Tags | Code |
|---|---|---|---|
| Nov-11-2017 | NEW APPLICATION ENTERED | NWAPI | |
| Nov-17-2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | NWOSI | |
| Feb-21-2018 | ASSIGNED TO EXAMINER | DOCKD | |
| Feb-21-2018 | NON-FINAL ACTION WRITTEN | CNRTR | |
| Feb-21-2018 | NON-FINAL ACTION E-MAILED | GNRTF | |
| Feb-21-2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED | GNRNO | |
| Jul-26-2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED | TROAI | |
| Jul-26-2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE | CRFAI | |
| Jul-26-2018 | TEAS/EMAIL CORRESPONDENCE ENTERED | TEMEI | |
| Jul-27-2018 | APPROVED FOR PUB - PRINCIPAL REGISTER | CNSAP | |
| Aug-15-2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | NONPE | |
| Sep-04-2018 | PUBLISHED FOR OPPOSITION | PUBOA | |
| Sep-04-2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | NPUBE | |
| Oct-30-2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | NOAME | |
| Feb-08-2019 | TEAS STATEMENT OF USE RECEIVED | EISUI | |
| Feb-27-2019 | CASE ASSIGNED TO INTENT TO USE PARALEGAL | AITUA | |
| Feb-08-2019 | USE AMENDMENT FILED | IUAFS | |
| Mar-04-2019 | STATEMENT OF USE PROCESSING COMPLETE | SUPCI | |
| Mar-18-2019 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | CNPRP | |
| Mar-19-2019 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | SUNAE | |
| Apr-23-2019 | REGISTERED-PRINCIPAL REGISTER | R.PRA | |
| Apr-23-2024 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | REM1E | |
| Apr-23-2025 | TEAS SECTION 8 & 15 RECEIVED | E815I | |
| Aug-29-2025 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | APREA | |
| Aug-29-2025 | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | C15AO | |
| Aug-29-2025 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | NA85E |